Reforming the 340B Drug Pricing Program Tradeoffs Between Hospital and Manufacturer Revenues

coapharm2018-05-22T13:01:23+00:00May 22, 2018|

Drugs to Move From Doctors’ Offices to Prescriptions Under Trump Plan

coapharm2018-05-21T13:35:55+00:00May 21, 2018|

Powerful, secretive middlemen affect drug prices

coapharm2018-05-21T13:35:13+00:00May 21, 2018|

Get Docs Out of Drug-Buying Business, HHS Chief Urges

coapharm2018-05-21T13:34:30+00:00May 21, 2018|

Four big questions about Trump’s plan to lower drug prices

coapharm2018-05-21T13:33:47+00:00May 21, 2018|

Pulse Check: Azar to drug plan critics: Bring on the fight

coapharm2018-05-18T14:02:42+00:00May 18, 2018|

CMS Administrator Seema Verma promotes cuts to 340B drug payments

coapharm2018-05-18T13:57:48+00:00May 18, 2018|

CMS spent the most on these 20 Medicare Part B & Part D drugs

coapharm2018-05-18T13:56:59+00:00May 18, 2018|

F.D.A. Names and Shames Drug Makers to Encourage Generic Competition

coapharm2018-05-17T14:02:30+00:00May 17, 2018|

Cancer groups approach drug price overhaul with caution

coapharm2018-05-17T13:57:20+00:00May 17, 2018|